Sinil Pharmaceutical Past Earnings Performance
Past criteria checks 4/6
Sinil Pharmaceutical has been growing earnings at an average annual rate of 18.3%, while the Pharmaceuticals industry saw earnings growing at 7.8% annually. Revenues have been growing at an average rate of 10.7% per year. Sinil Pharmaceutical's return on equity is 10.5%, and it has net margins of 16.4%.
Key information
18.3%
Earnings growth rate
17.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 10.7% |
| Return on equity | 10.5% |
| Net Margin | 16.4% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Little Excitement Around Sinil Pharmaceutical Co., Ltd.'s (KOSDAQ:012790) Earnings
Aug 12
Are Sinil Pharmaceutical Co., Ltd.'s (KOSDAQ:012790) Mixed Financials Driving The Negative Sentiment?
Mar 11Is Sinil Pharmaceutical's (KOSDAQ:012790) 122% Share Price Increase Well Justified?
Feb 13
Could The Sinil Pharmaceutical Co., Ltd. (KOSDAQ:012790) Ownership Structure Tell Us Something Useful?
Jan 17Sinil Pharmaceutical's (KOSDAQ:012790) Earnings Are Growing But Is There More To The Story?
Dec 22Are Sinil Pharmaceutical Co., Ltd.'s (KOSDAQ:012790) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?
Nov 26Revenue & Expenses Breakdown
How Sinil Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 91,699 | 15,066 | 21,580 | 2,651 |
| 30 Jun 24 | 96,516 | 15,763 | 21,752 | 2,712 |
| 31 Mar 24 | 90,064 | 13,505 | 20,546 | 2,958 |
| 31 Dec 23 | 89,135 | 13,641 | 19,938 | 2,979 |
| 30 Sep 23 | 86,210 | 12,624 | 19,751 | 4,080 |
| 30 Jun 23 | 81,163 | 11,613 | 19,175 | 3,769 |
| 31 Mar 23 | 83,914 | 13,444 | 18,738 | 3,521 |
| 31 Dec 22 | 80,007 | 12,157 | 18,032 | 3,264 |
| 30 Sep 22 | 75,971 | 11,067 | 17,270 | 1,627 |
| 30 Jun 22 | 72,082 | 10,343 | 16,561 | 1,325 |
| 31 Mar 22 | 66,435 | 8,229 | 15,768 | 833 |
| 31 Dec 21 | 61,754 | 6,679 | 15,735 | 195 |
| 30 Sep 21 | 60,177 | 5,201 | 16,124 | 294 |
| 30 Jun 21 | 59,435 | 5,407 | 16,167 | 426 |
| 31 Mar 21 | 59,323 | 6,494 | 16,198 | 740 |
| 31 Dec 20 | 61,438 | 7,544 | 16,195 | 785 |
| 30 Sep 20 | 63,736 | 8,359 | 14,821 | 1,003 |
| 30 Jun 20 | 63,613 | 8,072 | 15,069 | 775 |
| 31 Mar 20 | 63,547 | 8,017 | 15,220 | 466 |
| 31 Dec 19 | 60,648 | 7,257 | 14,446 | 530 |
| 30 Sep 19 | 57,397 | 7,115 | 14,992 | 316 |
| 30 Jun 19 | 54,252 | 5,497 | 14,109 | 1,005 |
| 31 Mar 19 | 53,241 | 4,767 | 13,836 | 1,029 |
| 31 Dec 18 | 53,277 | 5,714 | 13,809 | 853 |
| 30 Sep 18 | 52,442 | 6,385 | 13,492 | 824 |
| 30 Jun 18 | 52,867 | 7,888 | 13,426 | 135 |
| 31 Mar 18 | 51,369 | 8,293 | 12,936 | 108 |
| 31 Dec 17 | 50,942 | 8,198 | 12,865 | 93 |
| 30 Sep 17 | 50,545 | 7,731 | 13,107 | 73 |
| 30 Jun 17 | 49,387 | 8,376 | 12,783 | 73 |
| 31 Mar 17 | 49,158 | 8,840 | 13,017 | 75 |
| 31 Dec 16 | 50,212 | 9,360 | 12,389 | 64 |
| 30 Sep 16 | 49,134 | 9,432 | 11,803 | 5 |
| 30 Jun 16 | 48,151 | 9,352 | 11,502 | 9 |
| 31 Mar 16 | 46,964 | 9,117 | 11,331 | 29 |
| 31 Dec 15 | 44,703 | 8,764 | 11,109 | 24 |
| 30 Sep 15 | 45,240 | 9,405 | 10,925 | 74 |
| 30 Jun 15 | 46,805 | 9,905 | 11,099 | 77 |
| 31 Mar 15 | 47,662 | 10,247 | 11,187 | 57 |
| 31 Dec 14 | 48,160 | 10,179 | 11,553 | 57 |
| 30 Sep 14 | 46,421 | 8,927 | 11,965 | 7 |
| 30 Jun 14 | 45,514 | 8,740 | 12,006 | 0 |
| 31 Mar 14 | 44,448 | 7,977 | 11,917 | 0 |
| 31 Dec 13 | 44,311 | 7,324 | 12,121 | 125 |
Quality Earnings: A012790 has high quality earnings.
Growing Profit Margin: A012790's current net profit margins (16.4%) are higher than last year (14.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A012790's earnings have grown by 18.3% per year over the past 5 years.
Accelerating Growth: A012790's earnings growth over the past year (19.3%) exceeds its 5-year average (18.3% per year).
Earnings vs Industry: A012790 earnings growth over the past year (19.3%) did not outperform the Pharmaceuticals industry 22%.
Return on Equity
High ROE: A012790's Return on Equity (10.5%) is considered low.